Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

Key Points

• Chronic myeloid leukemia treatment intolerance heightens financial strain on oncology practices, adversely affecting patient care and staff retention.
• Economic burden from uncompensated tasks may threaten the viability of oncology practices.
• Analysis of resource demands highlights the significant impact of non-reimbursed duties on financial sustainability.
• These findings underscore the urgent need for addressing the issues surrounding treatment intolerance in cancer care.